{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:39:36Z","timestamp":1787168376890,"version":"build-2736575974"},"reference-count":209,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer-related deaths are approaching 10 million each year. Survival statistics for some cancers, such as ovarian cancer, have remained unchanged for decades, with women diagnosed at stage III or IV having over 80% chance of a lethal cancer recurrence after standard first-line treatment (reductive surgery and chemotherapy). New treatments and adjunct therapies are needed. In ovarian cancer, as in other cancers, the immune response, particularly cytotoxic (CD8+) T cells are correlated with a decreased risk of recurrence. As well as completely new antigen targets resulting from DNA mutations (neo-antigens), these T cells recognize cancer-associated overexpressed, re-expressed or modified self-proteins. However, there is concern that activation of self-reactive responses may also promote off-target pathology. This review considers the complex interplay between cancer-reactive and self-reactive immune cells and discusses the potential uses for various leading immunomodulatory compounds, derived from plant-based sources, as a cancer therapy option or to modulate potential autoimmune pathology. Along with reviewing well-studied compounds such as curcumin (from turmeric), epigallocatechin gallate (EGCG, from green tea) and resveratrol (from grapes and certain berries), it is proposed that compounds from novel sources, for example, native Australian plants, will provide a useful source for the fine modulation of cancer immunity in patients.<\/jats:p>","DOI":"10.3390\/cancers12030673","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T08:58:59Z","timestamp":1584089939000},"page":"673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells"],"prefix":"10.3390","volume":"12","author":[{"given":"Rhiane","family":"Moody","sequence":"first","affiliation":[{"name":"School of Health and Biomedical Sciences, RMIT, Bundoora 3083, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-9611","authenticated-orcid":false,"given":"Kirsty","family":"Wilson","sequence":"additional","affiliation":[{"name":"School of Health and Biomedical Sciences, RMIT, Bundoora 3083, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jaworowski","sequence":"additional","affiliation":[{"name":"School of Health and Biomedical Sciences, RMIT, Bundoora 3083, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-3667","authenticated-orcid":false,"given":"Magdalena","family":"Plebanski","sequence":"additional","affiliation":[{"name":"School of Health and Biomedical Sciences, RMIT, Bundoora 3083, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamaoncol.2015.3934","article-title":"Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: A report from the us food and drug administration","volume":"2","author":"Kazandjian","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase ii imvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1084\/jem.188.1.205","article-title":"B7-1 engagement of cytotoxic t lymphocyte antigen 4 inhibits t cell activation in the absence of cd28","volume":"188","author":"Fallarino","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"Ctla-4 and pd-1 receptors inhibit t-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-pd-1 and anti-pd-l1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of pd-1 versus pd-l1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-ctla-4 treatment (checkmate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2018.04.026","article-title":"Adverse events and responses in patients with recurrent ovarian cancer undergoing early-phase immune checkpoint inhibitor clinical trials","volume":"149","author":"Hinchcliff","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clinthera.2018.02.011","article-title":"Diagnosis and management of immune checkpoint inhibitor-related toxicities in ovarian cancer: A series of case vignettes","volume":"40","author":"Johnson","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"Singh, M., and Salnikova, M. (2015). Chapter 16\u2014T-cell immunotherapy for cancer. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies, Academic Press."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: Putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.aaa1292","article-title":"Detection of self-reactive cd8(+) t cells with an anergic phenotype in healthy individuals","volume":"346","author":"Maeda","year":"2014","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/0008-5472.CAN-14-2538","article-title":"Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge","volume":"75","author":"Makkouk","year":"2015","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.it.2015.12.005","article-title":"Re-examining the nature and function of self-reactive t cells","volume":"37","author":"Richards","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1055-9965.EPI-17-0752","article-title":"Autoantibodies against hsf1 and ccdc155 as biomarkers of early-stage, high-grade serous ovarian cancer","volume":"27","author":"Wilson","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","article-title":"P53-reactive t cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy","volume":"24","author":"Hardwick","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1083672","DOI":"10.1080\/2162402X.2015.1083672","article-title":"Novel understanding of self-reactive t cells","volume":"5","author":"Andersen","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0952-7915(02)00406-5","article-title":"Making and breaking tolerance","volume":"14","author":"Ohashi","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1189\/jlb.1A0913-500RR","article-title":"Inflammation programs self-reactive cd8+ t cells to acquire t-box-mediated effector function but does not prevent deletional tolerance","volume":"96","author":"Jackson","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"30539","DOI":"10.18632\/oncotarget.25669","article-title":"A diagnostic autoantibody signature for primary cutaneous melanoma","volume":"9","author":"Zaenker","year":"2018","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1078-0432.CCR-10-1363","article-title":"Immunobiomarkers in small cell lung cancer: Potential early cancer signals","volume":"17","author":"Chapman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/pr100686b","article-title":"Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer","volume":"10","author":"Anderson","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ijc.27667","article-title":"Tumor-associated autoantibody signature for the early detection of gastric cancer","volume":"132","author":"Zayakin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/pr500908n","article-title":"Autoantibody signature for the serologic detection of ovarian cancer","volume":"14","author":"Anderson","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ijc.22710","article-title":"P53-specific t cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy","volume":"121","author":"Lambeck","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_37","unstructured":"AIHW (2019). Cancer in Australia 2019."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., and Honma, Y. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6150-y"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with nivo or nivo+ipi: A systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/COC.0b013e3182467d90","article-title":"Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer","volume":"36","author":"Kim","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2018.02298","article-title":"Prognostic implications of heterogeneity in intra-tumoral immune composition for recurrence in early stage lung cancer","volume":"9","author":"Mony","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral t cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating t cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial t cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and brca1 loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nri1983","article-title":"Perforin-mediated target-cell death and immune homeostasis","volume":"6","author":"Voskoboinik","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2012-07-446146","article-title":"Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack","volume":"121","author":"Lopez","year":"2013","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5114\/ceji.2017.72823","article-title":"Myeloid-derived suppressor cells in ovarian cancer: Friend or foe?","volume":"42","author":"Walankiewicz","year":"2017","journal-title":"Cent. -Eur. J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory t cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/eji.200940022","article-title":"Co-expression of tnfr2 and cd25 identifies more of the functional cd4+foxp3+ regulatory t cells in human peripheral blood","volume":"40","author":"Chen","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","article-title":"Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of t regulatory cells","volume":"117","author":"Taylor","year":"2006","journal-title":"Immunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"Tgf-beta inhibits the activation and functions of nk cells by repressing the mtor pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","article-title":"Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients","volume":"6","author":"Truxova","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.18632\/oncotarget.26199","article-title":"Peritoneal nk cells are responsive to il-15 and percentages are correlated with outcome in advanced ovarian cancer patients","volume":"9","author":"Maas","year":"2018","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Milne, K., Kobel, M., Kalloger, S.E., Barnes, R.O., Gao, D., Gilks, C.B., Watson, P.H., and Nelson, B.H. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals cd20, foxp3 and tia-1 as positive prognostic factors. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006412"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1413","article-title":"Helping the cd8(+) t-cell response","volume":"4","author":"Bevan","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"Cd4 t cells: Fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial cd8+ tumor-infiltrating lymphocytes and a high cd8+\/regulatory t cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7785\/tcrt.2012.500312","article-title":"Expression of m2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer","volume":"12","author":"Lan","year":"2013","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-4-30","article-title":"Monocyte\/macrophage and t-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease","volume":"4","author":"Wang","year":"2006","journal-title":"J. Transl. Med."},{"key":"ref_64","first-page":"e1386362","article-title":"The t cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"Koelzer","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and her2\/neu-specific vaccination in patients with metastatic breast cancer","volume":"27","author":"Disis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/DDDT.S188925","article-title":"A brief report of toxicity end points of her2 vaccines for the treatment of patients with her2(+) breast cancer","volume":"13","author":"Costa","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/gyno.1998.5101","article-title":"Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer","volume":"72","author":"Gadducci","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1073\/pnas.92.2.432","article-title":"Breast and ovarian cancer-specific cytotoxic t lymphocytes recognize the same her2\/neu-derived peptide","volume":"92","author":"Peoples","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0960-7404(10)80030-1","article-title":"In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from her2\/neu induces cytotoxicity against autologous tumour","volume":"4","author":"Linehan","year":"1995","journal-title":"Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-1081-8","article-title":"Phase i\/ii randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission","volume":"61","author":"Chu","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","article-title":"Current challenges for cancer vaccine adjuvant development","volume":"17","author":"Bowen","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase iii trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1102\/1470-7330.2007.0030","article-title":"Cytoreductive surgery in ovarian cancer","volume":"7","author":"Pomel","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bpobgyn.2016.10.001","article-title":"Surgical treatment of early-stage ovarian cancer","volume":"41","author":"Trimbos","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-019-0247-4","article-title":"Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells","volume":"14","author":"Zhang","year":"2019","journal-title":"Infect. Agent Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zong, X., and Nephew, K.P. (2019). Ovarian cancer stem cells: Role in metastasis and opportunity for therapeutic targeting. Cancers, 11.","DOI":"10.3390\/cancers11070934"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biocel.2018.11.012","article-title":"Ovarian cancer stem cells and their role in drug resistance","volume":"106","author":"Pieterse","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral t-cell lymphoma-not otherwise specified and angioimmunoblastic t-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in sweden-stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"Figo\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rodriguez, G.M., Galpin, K.J.C., McCloskey, C.W., and Vanderhyden, B.C. (2018). The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers, 10.","DOI":"10.3390\/cancers10080242"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1002\/cncr.32520","article-title":"Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?","volume":"125","year":"2019","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to pd-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"Parp inhibition: Parp1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through sting-mediated t-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"Parp inhibition elicits sting-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"Parpi triggers the sting-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of brcaness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"Ctla-4 blockade synergizes therapeutically with parp inhibition in brca1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"212540","DOI":"10.7573\/dic.212540","article-title":"Advances in the use of parp inhibitor therapy for breast cancer","volume":"7","author":"McCann","year":"2018","journal-title":"Drugs Context"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI16153","article-title":"Histone deacetylase inhibitors modulate renal disease in the mrl-lpr\/lpr mouse","volume":"111","author":"Mishra","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of mhc class i, ii, and cd40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3\u2013dependent expression of mhc class i\u2013related chain a and b","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Bandolik, J.J., Hamacher, A., Schrenk, C., Weishaupt, R., and Kassack, M.U. (2019). Class i-histone deacetylase (hdac) inhibition is superior to pan-hdac inhibition in modulating cisplatin potency in high grade serous ovarian cancer cell lines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123052"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9363040","DOI":"10.1155\/2017\/9363040","article-title":"Natural bioactive compounds: Alternative approach to the treatment of glioblastoma multiforme","volume":"2017","author":"Desai","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jep.2013.12.023","article-title":"Fruit-derived phenolic compounds and pancreatic cancer: Perspectives from australian native fruits","volume":"152","author":"Vuong","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Sudhakaran, M., Sardesai, S., and Doseff, A.I. (2019). Flavonoids: New frontier for immuno-regulation and breast cancer control. Antioxidants, 8.","DOI":"10.3390\/antiox8040103"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbamcr.2007.04.015","article-title":"Curcumin reverses breast tumor exosomes mediated immune suppression of nk cell tumor cytotoxicity","volume":"1773","author":"Zhang","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12935-019-0981-0","article-title":"(-)-epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.21873\/anticanres.13720","article-title":"Chemoprevention of prostate cancer by natural agents: Evidence from molecular and epidemiological studies","volume":"39","author":"Mokbel","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3389\/fimmu.2019.00729","article-title":"Polyphenols: Immunomodulatory and therapeutic implication in colorectal cancer","volume":"10","author":"Mileo","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejmech.2017.12.039","article-title":"Natural compounds and combination therapy in colorectal cancer treatment","volume":"144","author":"Rejhova","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.3390\/molecules190811679","article-title":"Review of natural compounds for potential skin cancer treatment","volume":"19","author":"Chinembiri","year":"2014","journal-title":"Molecules"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.biopha.2018.04.113","article-title":"Plant derived anticancer agents: A green approach towards skin cancers","volume":"103","author":"Ijaz","year":"2018","journal-title":"Biomed. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/1535-7163.MCT-09-0377","article-title":"Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines","volume":"8","author":"Bill","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yahfoufi, N., Alsadi, N., Jambi, M., and Matar, C. (2018). The immunomodulatory and anti-inflammatory role of polyphenols. Nutrients, 10.","DOI":"10.3390\/nu10111618"},{"key":"ref_114","unstructured":"Giada, M. (2013). Food Phenolic Compounds: Main Classes, Sources and Their Antioxidant Power, Oxidative Stress and Chronic Degenerative Diseases \u2013 A Role for Antioxidants. IntechOpen, 87\u2013112."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1039\/c2fo30110e","article-title":"Antioxidant capacities, phenolic compounds and polysaccharide contents of 49 edible macro-fungi","volume":"3","author":"Guo","year":"2012","journal-title":"Food Funct."},{"key":"ref_116","first-page":"589","article-title":"Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, agaricus blazei murill kyowa, in gynecological cancer patients undergoing chemotherapy","volume":"14","author":"Ahn","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.mam.2011.10.001","article-title":"Green tea egcg, t cells, and t cell-mediated autoimmune diseases","volume":"33","author":"Wu","year":"2012","journal-title":"Mol. Asp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1189\/jlb.3A0514-261RR","article-title":"Epigallocatechin-3-gallate ameliorates autoimmune arthritis by reciprocal regulation of t helper-17 regulatory t cells and inhibition of osteoclastogenesis by inhibiting stat3 signaling","volume":"100","author":"Lee","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Negri, A., Naponelli, V., Rizzi, F., and Bettuzzi, S. (2018). Molecular targets of epigallocatechin-gallate (egcg): A special focus on signal transduction and cancer. Nutrients, 10.","DOI":"10.3390\/nu10121936"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Malaguarnera, L. (2019). Influence of resveratrol on the immune response. Nutrients, 11.","DOI":"10.3390\/nu11050946"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Czop, M., Bogucka-Kocka, A., Kubrak, T., Knap-Czop, K., Makuch-Kocka, A., Galkowski, D., Wawer, J., Kocki, T., and Kocki, J. (2019). Imaging flow cytometric analysis of stilbene-dependent apoptosis in drug resistant human leukemic cell lines. Molecules, 24.","DOI":"10.3390\/molecules24101896"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"65743","DOI":"10.18632\/oncotarget.19445","article-title":"Resveratrol promotes mica\/b expression and natural killer cell lysis of breast cancer cells by suppressing c-myc\/mir-17 pathway","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2012.12.093","article-title":"Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase","volume":"431","author":"Noh","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2014.07.004","article-title":"Interferon gamma induced by resveratrol analog, hs-1793, reverses the properties of tumor associated macrophages","volume":"22","author":"Jeong","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.4049\/jimmunol.1300606","article-title":"Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory b cells","volume":"191","author":"Bodogai","year":"2013","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.intimp.2007.12.006","article-title":"Resveratrol induces the suppression of tumor-derived cd4+cd25+ regulatory t cells","volume":"8","author":"Yang","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1080\/10408398.2018.1537237","article-title":"The immunomodulatory potential of natural compounds in tumor-bearing mice and humans","volume":"59","author":"Pan","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10875-006-9066-7","article-title":"\"Spicing up\" of the immune system by curcumin","volume":"27","author":"Jagetia","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.4110\/in.2019.19.e35","article-title":"Curcumin elevates tfh cells and germinal center b cell response for antibody production in mice","volume":"19","author":"Kim","year":"2019","journal-title":"Immune Netw."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Focaccetti, C., Izzi, V., Benvenuto, M., Fazi, S., Ciuffa, S., Giganti, M.G., Potenza, V., Manzari, V., Modesti, A., and Bei, R. (2019). Polyphenols as immunomodulatory compounds in the tumor microenvironment: Friends or foes?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071714"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2019.06.001","article-title":"Modulation of regulatory t cells by natural products in cancer","volume":"459","author":"Bahrami","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.15406\/moji.2018.06.00189","article-title":"Regulatory t cells in gynecologic cancer","volume":"6","author":"Ou","year":"2018","journal-title":"MOJ Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fimmu.2017.01482","article-title":"Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-expressing regulatory t cells","volume":"8","author":"Kampan","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clim.2013.07.003","article-title":"Impaired th1 immunity in ovarian cancer patients is mediated by tnfr2+tregs within the tumor microenvironment","volume":"149","author":"Govindaraj","year":"2013","journal-title":"Clin. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"104353","DOI":"10.1016\/j.phrs.2019.104353","article-title":"Targeting regulatory t cells by curcumin: A potential for cancer immunotherapy","volume":"147","author":"Shafabakhsh","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/jcb.26302","article-title":"Curcumin converts foxp3+ regulatory t cells to t helper 1 cells in patients with lung cancer","volume":"119","author":"Zou","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_137","first-page":"1866","article-title":"Curcumin up regulates t helper 1 cells in patients with colon cancer","volume":"9","author":"Xu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.archoralbio.2018.04.015","article-title":"Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma","volume":"92","author":"Liao","year":"2018","journal-title":"Arch. Oral Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cmi.2010.11","article-title":"Curcumin reverses t cell-mediated adaptive immune dysfunctions in tumor-bearing hosts","volume":"7","author":"Bhattacharyya","year":"2010","journal-title":"Cell. Mol. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/039463201302600111","article-title":"Regulatory t-cell modulation by green tea in chronic lymphocytic leukemia","volume":"26","author":"Simeon","year":"2013","journal-title":"Int. J. Immunopathol. Pharm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.prp.2017.09.006","article-title":"Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells","volume":"213","author":"Liu","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jgh.13069","article-title":"Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation","volume":"31","author":"Wubetu","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4143\/crt.2004.36.5.315","article-title":"Activity of green tea polyphenol epigallocatechin-3-gallate against ovarian carcinoma cell lines","volume":"36","author":"Kim","year":"2004","journal-title":"Cancer Res. Treat."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ygyno.2004.05.031","article-title":"Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines","volume":"94","author":"Huh","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1349-7006.2010.01805.x","article-title":"New cancer treatment strategy using combination of green tea catechins and anticancer drugs","volume":"102","author":"Suganuma","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Rawangkan, A., Wongsirisin, P., Namiki, K., Iida, K., Kobayashi, Y., Shimizu, Y., Fujiki, H., and Suganuma, M. (2018). Green tea catechin is an alternative immune checkpoint inhibitor that inhibits pd-l1 expression and lung tumor growth. Molecules, 23.","DOI":"10.3390\/molecules23082071"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green tea catechin, epigallocatechin-3-gallate (egcg): Mechanisms, perspectives and clinical applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharm."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2217\/epi.13.57","article-title":"Epigenetic effects of green tea polyphenols in cancer","volume":"5","author":"Henning","year":"2013","journal-title":"Epigenomics"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Jang, J.Y., Lee, J.K., Jeon, Y.K., and Kim, C.W. (2013). Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and m2 polarization. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-421"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1039\/c3fo60076a","article-title":"Immunomodulating effects of epigallocatechin-3-gallate from green tea: Mechanisms and applications","volume":"4","author":"Pae","year":"2013","journal-title":"Food Funct."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mukherjee, S., Baidoo, J.N.E., Sampat, S., Mancuso, A., David, L., Cohen, L.S., Zhou, S., and Banerjee, P. (2018). Liposomal tricurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia\/macrophages, and eliminates glioblastoma (gbm) and gbm stem cells. Molecules, 23.","DOI":"10.3390\/molecules23010201"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/mt.2015.165","article-title":"Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model","volume":"24","author":"Lu","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Zhang, X., Tian, W., Cai, X., Wang, X., Dang, W., Tang, H., Cao, H., Wang, L., and Chen, T. (2013). Hydrazinocurcumin encapsuled nanoparticles \"re-educate\" tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following stat3 suppression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065896"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2011.1298","article-title":"The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via stat3 inhibition","volume":"40","author":"Wang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.saa.2012.12.041","article-title":"Synthesis and characterization of ligational behavior of curcumin drug towards some transition metal ions: Chelation effect on their thermal stability and biological activity","volume":"105","author":"Refat","year":"2013","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2147\/IJN.S131973","article-title":"Polyphenol nanoformulations for cancer therapy: Experimental evidence and clinical perspective","volume":"12","author":"Masoomzadeh","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2016.12.030","article-title":"Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles","volume":"518","author":"Tyagi","year":"2017","journal-title":"Int. J. Pharm"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Granja, A., Pinheiro, M., and Reis, S. (2016). Epigallocatechin gallate nanodelivery systems for cancer therapy. Nutrients, 8.","DOI":"10.3390\/nu8050307"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.nano.2014.05.007","article-title":"Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo","volume":"10","author":"Siddiqui","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3892\/ol.2015.2851","article-title":"Cell death pathway induced by resveratrol-bovine serum albumin nanoparticles in a human ovarian cell line","volume":"9","author":"Guo","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-8490.81955","article-title":"An examination of the medicinal potential of scaevola spinescens: Toxicity, antibacterial, and antiviral activities","volume":"3","author":"Cock","year":"2011","journal-title":"Pharmacogn. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.foodchem.2015.07.032","article-title":"Identification and quantification of phenolics in australian native mint (mentha australis r. Br.)","volume":"192","author":"Tang","year":"2016","journal-title":"Food Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.foodres.2011.02.023","article-title":"Nutritional properties of commercially grown native australian fruits: Lipophilic antioxidants and minerals","volume":"44","author":"Konczak","year":"2011","journal-title":"Food Res. Int."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1080\/10942912.2011.580485","article-title":"Screening for antioxidant activity, phenolic content, and flavonoids from australian native food plants","volume":"16","author":"Sommano","year":"2013","journal-title":"Int. J. Food Prop."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/01635581.2011.535953","article-title":"Native australian fruit polyphenols inhibit cell viability and induce apoptosis in human cancer cell lines","volume":"63","author":"Tan","year":"2011","journal-title":"Nutr. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1021\/jf0622735","article-title":"Sources of antioxidant activity in australian native fruits. Identification and quantification of anthocyanins","volume":"54","author":"Netzel","year":"2006","journal-title":"J. Agric. Food Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.foodchem.2010.03.004","article-title":"Antioxidant capacity and phenolic compounds in commercially grown native australian herbs and spices","volume":"122","author":"Konczak","year":"2010","journal-title":"Food Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.toxrep.2014.06.011","article-title":"Anti-inflammatory potential of native australian herbs polyphenols","volume":"1","author":"Guo","year":"2014","journal-title":"Toxicol. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.4103\/0973-1296.157734","article-title":"The potential of selected australian medicinal plants with anti-proteus activity for the treatment and prevention of rheumatoid arthritis","volume":"11","author":"Cock","year":"2015","journal-title":"Pharm. Mag."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.foodchem.2012.07.089","article-title":"Cytoprotective and pro-apoptotic activities of native australian herbs polyphenolic-rich extracts","volume":"136","author":"Sakulnarmrat","year":"2013","journal-title":"Food Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01635581.2011.596646","article-title":"Potential antioxidant, antiinflammatory, and proapoptotic anticancer activities of kakadu plum and illawarra plum polyphenolic fractions","volume":"63","author":"Tan","year":"2011","journal-title":"Nutr. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1017\/S0007114512004333","article-title":"The australian fruit illawarra plum (podocarpus elatus endl., podocarpaceae) inhibits telomerase, increases histone deacetylase activity and decreases proliferation of colon cancer cells","volume":"109","author":"Symonds","year":"2013","journal-title":"Br. J. Nutr."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.foodres.2010.12.031","article-title":"Native australian fruit polyphenols inhibit cox-2 and inos expression in lps-activated murine macrophages","volume":"44","author":"Tan","year":"2011","journal-title":"Food Res. Int."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01635581.2011.538953","article-title":"Molecular pathways for cancer chemoprevention by dietary phytochemicals","volume":"63","author":"Tan","year":"2011","journal-title":"Nutr. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ptr.5256","article-title":"Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: An updated review of their molecular mechanisms and experimental models","volume":"29","author":"Parhiz","year":"2015","journal-title":"Phytother. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bmc.2016.11.006","article-title":"Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis","volume":"25","author":"Jung","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jcp.24818","article-title":"Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ros and activation of ask1\/jnk pathway","volume":"230","author":"Palit","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s13277-015-4176-6","article-title":"Hesperetin induces apoptosis of esophageal cancer cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species","volume":"37","author":"Wu","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/1567201812666151027142412","article-title":"Hesperetin liposomes for cancer therapy","volume":"13","author":"Wolfram","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Semwal, D.K., Semwal, R.B., Combrinck, S., and Viljoen, A. (2016). Myricetin: A dietary molecule with diverse biological activities. Nutrients, 8.","DOI":"10.3390\/nu8020090"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.foodchem.2013.01.009","article-title":"Inhibitory effects of myricetin on mammalian DNA polymerase, topoisomerase and human cancer cell proliferation","volume":"139","author":"Shiomi","year":"2013","journal-title":"Food Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/1535-7163.281.4.2","article-title":"Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells","volume":"4","author":"Ko","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.fct.2018.05.005","article-title":"Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by the iron-dependent generation of reactive oxygen species from hydrogen peroxide","volume":"118","author":"Knickle","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/cbin.10977","article-title":"Myricetin-induced oxidative stress suppresses murine t lymphocyte activation","volume":"42","author":"Maleki","year":"2018","journal-title":"Cell Biol. Int."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/BF02980240","article-title":"Inhibition of interleukin-2 production by myricetin in mouse el-4 t cells","volume":"30","author":"Cho","year":"2007","journal-title":"Arch. Pharm. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF02977791","article-title":"Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappab DNA binding activity by myricetin, a naturally occurring flavonoid","volume":"28","author":"Kang","year":"2005","journal-title":"Arch. Pharm. Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jsfa.5733","article-title":"Myricetin attenuates lipopolysaccharide-stimulated activation of mouse bone marrow-derived dendritic cells through suppression of ikk\/nf-\u03bab and mapk signalling pathways","volume":"93","author":"Fu","year":"2013","journal-title":"J. Sci. Food Agric."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Khan, F., Niaz, K., Maqbool, F., Ismail Hassan, F., Abdollahi, M., Nagulapalli Venkata, K.C., Nabavi, S.M., and Bishayee, A. (2016). Molecular targets underlying the anticancer effects of quercetin: An update. Nutrients, 8.","DOI":"10.3390\/nu8090529"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jn\/136.11.2862","article-title":"Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in f344 rats","volume":"136","author":"Dihal","year":"2006","journal-title":"J. Nutr."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0278-6915(99)00021-6","article-title":"Prevention of n-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice","volume":"37","author":"Khanduja","year":"1999","journal-title":"Food Chem. Toxicol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"596496","DOI":"10.1155\/2013\/596496","article-title":"Quercetin induces mitochondrial mediated apoptosis and protective autophagy in human glioblastoma u373mg cells","volume":"2013","author":"Kim","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11033-015-3921-7","article-title":"Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (pi3k) and protein kinase c (pkc) via induction of p53 in hepatocellular carcinoma (hepg2) cell line","volume":"42","author":"Maurya","year":"2015","journal-title":"Mol. Biol. Rep."},{"key":"ref_193","first-page":"1453","article-title":"Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via bcl-2 and bax regulation","volume":"5","author":"Duo","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-4889(02)00328-2","article-title":"The flavonoid, quercetin, differentially regulates th-1 (ifngamma) and th-2 (il4) cytokine gene expression by normal peripheral blood mononuclear cells","volume":"1593","author":"Nair","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.bjp.0706695","article-title":"Regulation of il-1-induced selective il-6 release from human mast cells and inhibition by quercetin","volume":"148","author":"Kempuraj","year":"2006","journal-title":"Br. J. Pharm."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.4049\/jimmunol.0903991","article-title":"Immunosuppressive effect of quercetin on dendritic cell activation and function","volume":"184","author":"Huang","year":"2010","journal-title":"J. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/1568009617666170427102729","article-title":"Impact of il-12 in cancer","volume":"17","author":"Lu","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.4188","article-title":"Tumour necrosis factor and cancer","volume":"230","author":"Waters","year":"2013","journal-title":"J. Pathol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/biof.50","article-title":"Improving tnf as a cancer therapeutic: Tailor-made tnf fusion proteins with conserved antitumor activity and reduced systemic side effects","volume":"35","author":"Gerspach","year":"2009","journal-title":"Biofactors"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: Still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"17359","DOI":"10.1074\/jbc.M600861200","article-title":"Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity","volume":"281","author":"Ding","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13075-019-2001-0","article-title":"Potential therapeutic effects of cyanidin-3-o-glucoside on rheumatoid arthritis by relieving inhibition of cd38+ nk cells on treg cell differentiation","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"52517","DOI":"10.18632\/oncotarget.9593","article-title":"Dietary phytochemicals and cancer chemoprevention: A review of the clinical evidence","volume":"7","author":"Kotecha","year":"2016","journal-title":"Oncotarget"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000314513","article-title":"Dietary polyphenols, deacetylases and chromatin remodeling in inflammation","volume":"101","author":"Rahman","year":"2010","journal-title":"World Rev. Nutr. Diet."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JEP.S70568","article-title":"New insights into therapeutic activity and anticancer properties of curcumin","volume":"9","author":"Panda","year":"2017","journal-title":"J. Exp. Pharm."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Ko, J.H., Sethi, G., Um, J.Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A., and Ahn, K.S. (2017). The role of resveratrol in cancer therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122589"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00262-018-2130-3","article-title":"Tricurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of hpv+ tumors","volume":"67","author":"Mukherjee","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.fct.2018.05.050","article-title":"Phytochemicals of herbs and spices: Health versus toxicological effects","volume":"119","author":"Guldiken","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.foodres.2016.08.004","article-title":"Organic acids in kakadu plum (terminalia ferdinandiana): The good (ellagic), the bad (oxalic) and the uncertain (ascorbic)","volume":"89","author":"Williams","year":"2016","journal-title":"Food Res. Int."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:06:36Z","timestamp":1760173596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":209,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cancers12030673"],"URL":"https:\/\/doi.org\/10.3390\/cancers12030673","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]}}}